Glioblastoma represents an attractive therapeutic target for peptide vaccination as the unique epidermal growth factor receptor (EGFR) variant, EGFRvIII,is expressed in approximately 30% of patients with glioblastoma [72]. Here, EGFR is linked to glioblastoma.